Junior Investigator Global ATTR Cardiac Amyloidosis Research RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Monday 29th, April 2024
External Deadline: Monday 6th, May 2024
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: March 18, 2024
Geographic Scope: France, Italy, Spain, Germany, Japan, Canada, Australia and South Korea
Clinical Area: ATTR Cardiac Amyloidosis
Link to full RFP: Junior Investigator Global ATTR Cardiac Amyloidosis Research
Application Due Date: May 6, 2024
Specific Area of Interest: Pfizer is interested in supporting research proposals that advance our understanding of early diagnosis and treatment of ATTR amyloidosis through research focused in the following areas:
- – Approaches for the early identification and follow up of ATTR Cardiac Amyloidosis patients
- – RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR Cardiac Amyloidosis
– Evaluation of patients with ATTR Cardiac Amyloidosis presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)8Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).